Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STHENOS
2023-507431-37-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, single-blind trial of ofatumumab in multiple sclerosis (MS) (2 arms), sponsored by Novartis. Primary endpoint: NEDA-3 status at end of study. Started Jul 2021; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-507431-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507431-37-00.